Literature DB >> 18191881

Willingness of Chinese injection drug users to participate in HIV vaccine trials.

Lu Yin1, Yuanzhi Zhang, Han-Zhu Qian, Baoling Rui, Lijiang Zhang, Junling Zhu, Yongsheng Guan, Yunxia Wang, Qingchun Li, Yuhua Ruan, Yiming Shao.   

Abstract

BACKGROUND: Chinese injection drug users (IDUs) may be a proper candidate population for HIV vaccine trials.
OBJECTIVE: To evaluate willingness to participate (WTP) in HIV vaccine trials among Chinese IDUs.
METHODS: Questionnaire interviews were completed among 401 IDUs in Urumqi City in northwestern China in 2005.
RESULTS: Overall 74.3% of participants said that they would be definitely willing to participate in HIV vaccine trials, 17.7% were probably willing, 6.2% were probably not willing, and remaining 1.8% were definitely not willing to join. Multivariate logistic regression analysis demonstrated that WTP was positively associated with having ever had sex with a drug use partner (adjusted odds ratio [AOR]: 1.8; 95% confidence interval [CI]: 1.04, 3.2), sharing needle and syringe with a new drug use partner in the past 3 months (AOR: 3.8; 95% CI: 1.2, 11.7), perceived family support for participation (AOR: 7.4; 95% CI: 4.3, 12.7), and perceived vaccine protection against HIV infection (AOR: 16.1; 95% CI: 3.7, 70.8), and was negatively associated with perceived risk of social stigma and isolation for participation (AOR: 0.3; 95% CI: 0.2, 0.5).
CONCLUSIONS: The stated WTP in hypothetical HIV vaccine trials was high among Chinese IDUs. Further studies are needed to evaluate actual enrollment into the trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18191881      PMCID: PMC2762822          DOI: 10.1016/j.vaccine.2007.11.091

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

1.  Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand.

Authors:  K M MacQueen; S Vanichseni; D Kitayaporn; L S Lin; A Buavirat; T Naiwatanakul; S Raktham; P Mock; W L Heyward; D C Des Jarlais; K Choopanya; T D Mastro
Journal:  J Acquir Immune Defic Syndr       Date:  1999-07-01       Impact factor: 3.731

2.  Who will enroll? Predicting participation in a phase II AIDS vaccine trial.

Authors:  S D Halpern; D S Metzger; J A Berlin; P A Ubel
Journal:  J Acquir Immune Defic Syndr       Date:  2001-07-01       Impact factor: 3.731

Review 3.  Past, present and future of HIV vaccine trials in developing countries.

Authors:  José Esparza; Saladin Osmanov; Claire Pattou-Markovic; Coumba Touré; Marie Louise Chang; Stephanie Nixon
Journal:  Vaccine       Date:  2002-05-06       Impact factor: 3.641

4.  HIV infection and sexually transmitted diseases in female commercial sex workers in China.

Authors:  Yanpeng Ding; Roger Detels; Zaiwei Zhao; Yong Zhu; Guanghui Zhu; Bowei Zhang; Tao Shen; Xueshan Xue
Journal:  J Acquir Immune Defic Syndr       Date:  2005-03-01       Impact factor: 3.731

5.  HIV incidence and factors contributed to retention in a 12-month follow-up study of injection drug users in Sichuan Province, China.

Authors:  Yuhua Ruan; Guangming Qin; Shizhu Liu; Hanzhu Qian; Li Zhang; Feng Zhou; Yixin He; Kanglin Chen; Lu Yin; Xianhuang Chen; Qinlin Hao; Hui Xing; Yanhui Song; Yunxia Wang; Kunxue Hong; Jianping Chen; Yiming Shao
Journal:  J Acquir Immune Defic Syndr       Date:  2005-08-01       Impact factor: 3.731

6.  Sexually transmitted infections among female sex workers in Yunnan, China.

Authors:  Xiang-Sheng Chen; Yue-Ping Yin; Guo-Jun Liang; Xiang-Dong Gong; Hua-Sheng Li; Gilles Poumerol; Nguyen Thuy; Mei-Qin Shi; Yan-Hua Yu
Journal:  AIDS Patient Care STDS       Date:  2005-12       Impact factor: 5.078

7.  Risk of HIV/AIDS in China: subpopulations of special importance.

Authors:  H Z Qian; Z H Qian; S H Vermund; N Wang
Journal:  Sex Transm Infect       Date:  2005-12       Impact factor: 3.519

8.  Changes in willingness to participate in HIV vaccine trials among HIV-negative injection drug users.

Authors:  Elizabeth T Golub; Lisa A Purvis; Marcella Sapun; Mahboobeh Safaeian; Chris Beyrer; David Vlahov; Steffanie A Strathdee
Journal:  AIDS Behav       Date:  2005-09

9.  A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant.

Authors:  S Piyasirisilp; F E McCutchan; J K Carr; E Sanders-Buell; W Liu; J Chen; R Wagner; H Wolf; Y Shao; S Lai; C Beyrer; X F Yu
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 10.  HIV vaccine preparedness studies in the organization for economic co-operation and development (OECD) countries.

Authors:  S Dhalla; R Woods; S A Strathdee; D M Patrick; R S Hogg
Journal:  AIDS Care       Date:  2007-06-13
View more
  13 in total

1.  Balancing collective responsibility, individual opportunities and risks: a qualitative study on how police officers reason around volunteering in an HIV vaccine trial in Dar es Salaam, Tanzania.

Authors:  Edith A M Tarimo; Anna Thorson; Thecla W Kohi; Joachim Mwami; Muhammad Bakari; Eric Sandström; Asli Kulane
Journal:  BMC Public Health       Date:  2010-05-28       Impact factor: 3.295

2.  Enhancing HIV vaccine trial consent preparedness among street drug users.

Authors:  Celia B Fisher
Journal:  J Empir Res Hum Res Ethics       Date:  2010-06       Impact factor: 1.742

3.  Cognitive factors and willingness to participate in an HIV vaccine trial among HIV-negative injection drug users.

Authors:  Shayesta Dhalla; Gary Poole; Joel Singer; David M Patrick; Evan Wood; Thomas Kerr
Journal:  Vaccine       Date:  2009-12-29       Impact factor: 3.641

4.  The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China.

Authors:  Lingjie Liao; Hui Xing; Hong Shang; Jingyun Li; Ping Zhong; Laiyi Kang; Hua Cheng; Xuefeng Si; Shulin Jiang; Xinping Li; Yiming Shao
Journal:  J Acquir Immune Defic Syndr       Date:  2010-02       Impact factor: 3.731

5.  Unpolarized release of vaccinia virus and HIV antigen by colchicine treatment enhances intranasal HIV antigen expression and mucosal humoral responses.

Authors:  Yan Zhang; Jingyi Yang; Rong Bao; Yaoqing Chen; Dihan Zhou; Benxia He; Maohua Zhong; Yaoming Li; Fang Liu; Qiaoli Li; Yi Yang; Chen Han; Ying Sun; Yuan Cao; Huimin Yan
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

6.  Willingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in China.

Authors:  Yuan Dong; Xiaoxing Shen; Ruizhang Guo; Baochi Liu; Lingyan Zhu; Jing Wang; Linxia Zhang; Jun Sun; Xiaoyan Zhang; Jianqing Xu
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

7.  Motivations to participate in a Phase I/II HIV vaccine trial: A descriptive study from Dar es Salaam, Tanzania.

Authors:  E A M Tarimo; M Bakari; D C V Kakoko; T W Kohi; F Mhalu; E Sandstrom; A Kulane
Journal:  BMC Public Health       Date:  2016-02-24       Impact factor: 3.295

8.  Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda.

Authors:  Gershim Asiki; Andrew Abaasa; Eugene Ruzagira; Freddie Kibengo; Ubaldo Bahemuka; Jerry Mulondo; Janet Seeley; Linda-Gail Bekker; Sinead Delany; Pontiano Kaleebu; Anatoli Kamali
Journal:  Vaccine       Date:  2013-09-07       Impact factor: 3.641

9.  Willingness to participate in clinical trials among patients of Chinese heritage: a meta-synthesis.

Authors:  Alexander Limkakeng; Amruta Phadtare; Jatin Shah; Meenakshi Vaghasia; Ding Ying Wei; Anand Shah; Ricardo Pietrobon
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

10.  HIV related high risk behaviors and willingness to participate in HIV vaccine trials among China MSM by computer assisted self-interviewing survey.

Authors:  Zhenxing Chu; Junjie Xu; Kathleen Heather Reilly; Chunming Lu; Qinghai Hu; Ning Ma; Min Zhang; Jing Zhang; Yongjun Jiang; Wenqing Geng; Hong Shang
Journal:  Biomed Res Int       Date:  2013-11-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.